• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Controversies in Modern Eye Care 2023: Evolving therapeutics for nAMD and DME


David Liao, MD, shares highlights from his discussion on evolving treatment strategies for neovascular AMD and DME, during the 17th annual Controversies in Modern Eye Care meeting.

David Liao, MD, of Retina Vitreous Associates Medical Group, shares highlights from his breakfast symposium, "Keeping an eye on evolving management strategies for nAMD and DME," which he co-presented during the 17th annual Controversies in Modern Eye Care symposium at the Skirball Cultural Center in Los Angeles, California.

This transcript has been edited for clarity.

David Liao, MD:

My name is David Liao, I'm with Retina Vitreous Associates here in Los Angeles. Today I'm gonna be speaking about evolving treatment strategies for neovascular AMD and DME. We're going to be going through a little bit of the history of how we got to where we are today, starting with the initial pivotal trials and fixed dosing regimens, and then we'll move on to the evolution of PRN treatment, and where we are today with some new medications, as well as the treatment extend protocol. And I think we'll see how the treatment has evolved over the years to minimize treatment burden and continue with good efficacy, as well.

You know, with all of these years of evolving treatments, we've kind of focused now on a more patient-centered approach. So it's individualize not only for the patient, but for their specific disease. And I think that really—the patients like it more, there's less risk for them, there's less burden of coming in, and it really keeps their disease really in control. So it's not too much treatment, but not too little either.

Related Videos
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
Thomas V. Johnson, MD, PhD, of Wilmer Eye Institute discusses his EyeCon 2023 presentation
© 2024 MJH Life Sciences

All rights reserved.